Loading clinical trials...
Loading clinical trials...
A Phase I/II Clinical Study of Anlotinib Hydrochloride Capsule Combined With Concurrent Chemoradiotherapy in the Treatment of Unresectable Stage III Non-small Cell Lung Cancer
Conditions
Interventions
Anlotinib hydrochloride capsule Combined With Concurrent Chemoradiotherapy
Locations
1
China
Shandong Cancer Hospital
Jinan, Shandong, China
Start Date
November 12, 2020
Primary Completion Date
November 20, 2021
Completion Date
November 22, 2021
Last Updated
February 25, 2022
NCT06043817
NCT07144280
NCT07431827
NCT06758401
NCT06427941
NCT06476808
Lead Sponsor
Shandong Cancer Hospital and Institute
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions